CL2014002857A1 - Uso de 18-metil-15beta,16beta-metilen-19-nor-20-espirox-4-en-3-onas de formula (1) en el tratamiento de trastornos con sangrado uterino y hemorragias; sistema intrauterino que comprende 18-metil-15beta,16beta-metilen-19-nor-20-espirox-4-en-3-onas de formula (1). - Google Patents

Uso de 18-metil-15beta,16beta-metilen-19-nor-20-espirox-4-en-3-onas de formula (1) en el tratamiento de trastornos con sangrado uterino y hemorragias; sistema intrauterino que comprende 18-metil-15beta,16beta-metilen-19-nor-20-espirox-4-en-3-onas de formula (1).

Info

Publication number
CL2014002857A1
CL2014002857A1 CL2014002857A CL2014002857A CL2014002857A1 CL 2014002857 A1 CL2014002857 A1 CL 2014002857A1 CL 2014002857 A CL2014002857 A CL 2014002857A CL 2014002857 A CL2014002857 A CL 2014002857A CL 2014002857 A1 CL2014002857 A1 CL 2014002857A1
Authority
CL
Chile
Prior art keywords
15beta
16beta
methylene
methyl
formula
Prior art date
Application number
CL2014002857A
Other languages
English (en)
Inventor
Harri Jukarainen
Henriikka Korolainen
Reinhard Nubbemeyer
Norbert Schmees
Lars Röse
Tuula Valo
Katja Prelle
Original Assignee
Bayer Pharma AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=48141995&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CL2014002857(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bayer Pharma AG filed Critical Bayer Pharma AG
Publication of CL2014002857A1 publication Critical patent/CL2014002857A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0034—Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
    • A61K9/0039—Devices retained in the uterus for a prolonged period, e.g. intrauterine devices for contraception
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Reproductive Health (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Urology & Nephrology (AREA)
  • Organic Chemistry (AREA)
  • Gynecology & Obstetrics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Indole Compounds (AREA)
  • Medicinal Preparation (AREA)
CL2014002857A 2012-04-23 2014-10-23 Uso de 18-metil-15beta,16beta-metilen-19-nor-20-espirox-4-en-3-onas de formula (1) en el tratamiento de trastornos con sangrado uterino y hemorragias; sistema intrauterino que comprende 18-metil-15beta,16beta-metilen-19-nor-20-espirox-4-en-3-onas de formula (1). CL2014002857A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE102012206653 2012-04-23

Publications (1)

Publication Number Publication Date
CL2014002857A1 true CL2014002857A1 (es) 2015-02-06

Family

ID=48141995

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2014002857A CL2014002857A1 (es) 2012-04-23 2014-10-23 Uso de 18-metil-15beta,16beta-metilen-19-nor-20-espirox-4-en-3-onas de formula (1) en el tratamiento de trastornos con sangrado uterino y hemorragias; sistema intrauterino que comprende 18-metil-15beta,16beta-metilen-19-nor-20-espirox-4-en-3-onas de formula (1).

Country Status (28)

Country Link
US (1) US20150119372A1 (es)
EP (1) EP2841073A1 (es)
JP (1) JP2015514789A (es)
KR (1) KR20150005548A (es)
CN (1) CN104379149A (es)
AR (1) AR090800A1 (es)
AU (1) AU2013251842A1 (es)
BR (1) BR112014026086A2 (es)
CA (1) CA2871001A1 (es)
CL (1) CL2014002857A1 (es)
CO (1) CO7111253A2 (es)
CR (1) CR20140489A (es)
CU (1) CU20140120A7 (es)
DO (1) DOP2014000240A (es)
EA (1) EA201491917A1 (es)
EC (1) ECSP14024263A (es)
GT (1) GT201400225A (es)
HK (1) HK1206271A1 (es)
IL (1) IL235096A0 (es)
MA (1) MA37443A1 (es)
MX (1) MX2014012848A (es)
PE (1) PE20142437A1 (es)
PH (1) PH12014502371A1 (es)
SG (1) SG11201406583QA (es)
TN (1) TN2014000445A1 (es)
TW (1) TW201345530A (es)
UY (1) UY34759A (es)
WO (1) WO2013160200A1 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN120754109B (zh) * 2024-11-08 2026-04-28 广州医科大学 β-榄香酮酸或其衍生物在制备预防和/或治疗多囊卵巢综合征药物中的应用

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PH30867A (en) 1992-07-31 1997-12-09 Leiras Oy Method and equipment for installing a medicine capsule on a support.
FI90627C (fi) 1992-07-31 1994-03-10 Leiras Oy Laitteisto lääkeainesauvan varustamiseksi vaipalla
FI107339B (fi) 1998-06-30 2001-07-13 Leiras Oy Lääkeaineiden läpäisynopeutta säätävä kalvo tai matriisi
US6056976A (en) 1998-11-12 2000-05-02 Leiras Oy Elastomer, its preparation and use
DE102006030416A1 (de) * 2006-06-29 2008-01-03 Bayer Schering Pharma Ag 18-Methyl-19-nor-androst-4-en-17,17-spiroether (18-Methyl-19-nor-20-spirox-4-en-3-one) sowie diese enthaltende pharmazeutische Präparate

Also Published As

Publication number Publication date
DOP2014000240A (es) 2015-02-15
CU20140120A7 (es) 2015-02-26
PE20142437A1 (es) 2015-01-31
CN104379149A (zh) 2015-02-25
WO2013160200A1 (de) 2013-10-31
MX2014012848A (es) 2015-02-05
UY34759A (es) 2013-11-29
AU2013251842A1 (en) 2014-11-06
ECSP14024263A (es) 2015-12-31
MA37443A1 (fr) 2016-05-31
TW201345530A (zh) 2013-11-16
EP2841073A1 (de) 2015-03-04
CR20140489A (es) 2014-12-24
CO7111253A2 (es) 2014-11-10
US20150119372A1 (en) 2015-04-30
EA201491917A1 (ru) 2015-04-30
TN2014000445A1 (en) 2016-03-30
SG11201406583QA (en) 2014-11-27
AR090800A1 (es) 2014-12-10
IL235096A0 (en) 2014-12-31
HK1206271A1 (en) 2016-01-08
PH12014502371A1 (en) 2015-01-12
JP2015514789A (ja) 2015-05-21
BR112014026086A2 (pt) 2017-07-18
GT201400225A (es) 2016-01-22
CA2871001A1 (en) 2013-10-31
KR20150005548A (ko) 2015-01-14

Similar Documents

Publication Publication Date Title
HUE053946T2 (hu) 4'-Fluor-nukleozidok, 4'-fluor-nukleotidok és analógjaik HCV kezelésére
SI2739615T1 (sl) Fenil-3-aza-biciklo(3.1.0)heks-3-il-metanoni in njihova uporaba kot zdravilo
LT3219316T (lt) Riebalų rūgščių mišinys (r.r.g., riebalų rūgščių grupė), skirtas naudoti uždegiminių patologijų gydymui
MX386055B (es) Uso de medicamentos para disminuir la evolución de la enfermedad de parkinson.
DOP2016000089A (es) Sistema de administracion intrauterina
UY35771A (es) Tienouracil-carboxamidas cíclicas y su uso
HRP20181554T4 (hr) Tauroursodezoksikolna kiselina (tudca), namijenjena upotrebi u liječenju neurodegenerativnih poremećaja
BR112014025416A2 (pt) AGENTES ANTIMALÁRICOS, COMPOSIÇÃO FARMACEUTICA COMPREENDENDO-OS E USO Dos MESMOS.
CL2015000537A1 (es) Siarn y su uso en los métodos y composiciones para el tratamiento y/o prevención de enfermedades de los ojos.
CL2014002857A1 (es) Uso de 18-metil-15beta,16beta-metilen-19-nor-20-espirox-4-en-3-onas de formula (1) en el tratamiento de trastornos con sangrado uterino y hemorragias; sistema intrauterino que comprende 18-metil-15beta,16beta-metilen-19-nor-20-espirox-4-en-3-onas de formula (1).
EP3048886A4 (en) 3, 4-bis-benzylsulfonylbutanenitrile and its pharmaceutical use
CL2014002836A1 (es) Uso intrauterino de 18-metil-15b,16b-metilen-19-nor-20-espirox-4-en-3-onas; sistema intrauterino que contiene 18-metil-15b,16b-metilen-19-nor-20-espirox-4-en-3-onas y su uso en la anticoncepcion y terapia ginecologica.
Al-Daghman One of the indications of addition in the Quranic context Manifestations of the intention of the appointment and the ratio by adding the pronoun (ha) to the formula (verbs) in the light of appropriate knowledge
Guang-Rong et al. Interpretation of the Relationship between Dissemination Effect Research and Learning Theory
Gravotta THE UNADVERTISED USES OF DRUGS
Karlsson et al. Externhandelns expansion: En (o) hållbar utveckling?
TH140148S (th) วาลว์สำหรับใช้ในทางการแพทย์
TH1701002334A (th) โครเมนซึ่งถูกแทนที่และวิธีการใช้
TH129678S (th) เก้าอี้
TH177205A (th) วิธีการสำหรับการบำบัดกลุ่มอาการอัลปอร์ท
AR098060A1 (es) Sistema de administración intrauterina
TH131907S (th) เข็มเจาะสำหรับให้สารละลาย
TH145629S (th) อุปกรณ์เจาะสำหรับการเก็บตัวอย่างเลือด
TH53437S1 (th) อุปกรณ์เจาะสำหรับการเก็บตัวอย่างเลือด
TH53436S1 (th) อุปกรณ์เจาะสำหรับการเก็บตัวอย่างเลือด